Epidemiological cutoff values (ECVs) for the Cryptococcus neoformans-Cryptococcus gattii species complex versus fluconazole, itraconazole, posaconazole, and voriconazole are not available. We established ECVs for these species and agents based on wildtype (WT) MIC distributions. A total of 2,985 to 5,733 CLSI MICs for C. neoformans (including isolates of molecular type VNI [MICs for 759 to 1,137 isolates] and VNII, VNIII, and VNIV [MICs for 24 to 57 isolates]) and 705 to 975 MICs for C. gattii (including 42 to 260 for VGI, VGII, VGIII, and VGIV isolates) were gathered in 15 to 24 laboratories (Europe, United States, and South Africa) and were aggregated for analysis. Additionally, 220 to 359 MICs measured using CLSI yeast nitrogen base (YNB) medium instead of CLSI RPMI medium for C. neoformans were evaluated. CLSI RPMI medium ECVs for distributions originating from at least three laboratories, which included >95% of the modeled WT population, were as follows: fluconazole, 8 g/ml (VNI, C. gattii nontyped, VGI, VGIIa, and VGIII), 16 g/ml (C. neoformans nontyped, VNIII, and VGIV), and 32 g/ml (VGII); itraconazole, 0.25 g/ml (VNI), 0.5 g/ml (C. neoformans and C. gattii nontyped and VGI to VGIII), and 1 g/ml (VGIV); posaconazole, 0.25 g/ml (C. neoformans nontyped and VNI) and 0.5 g/ml (C. gattii nontyped and VGI); and voriconazole, 0.12 g/ml (VNIV), 0.25 g/ml (C. neoformans and C. gattii nontyped, VNI, VNIII, VGII, and VGIIa,), and 0.5 g/ml (VGI). The number of laboratories contributing data for other molecular types was too low to ascertain that the differences were due to factors other than assay variation. In the absence of clinical breakpoints, our ECVs may aid in the detection of isolates with acquired resistance mechanisms and should be listed in the revised CLSI
T he Cryptococcus neoformans-Cryptococcus gattii complex is the most common species of non-Candida yeasts recovered from clinical specimens (32.9% of 8,717 isolates) (41) . In addition, cryptococcal disease has been reported as the second most common severe fungal infection in certain regions (41) . Infections caused by C. neoformans var. grubii (serotype A) and, to a lesser degree, by C. neoformans var. neoformans (serotype D) are seen worldwide among immunocompromised hosts (4) . The more geographically restricted C. gattii (serotypes B and C) causes infections among immunocompromised as well as nonimmunocompromised patients, and the infections are more difficult to treat (27, 38) . Irrespective of the species, cryptococcal disease is associated with high mortality rates (Ն12.7%) (15, 17, 38) . Using molecular methodologies, eight major molecular types have been identified among the four serotypes and their hybrids (4, 6, 8, 25, 31, 51) . C. neoformans comprises molecular types VNI and VNII (both serotype A), VNIII (serotype A/D hybrid), and VNIV (serotype D), while C. gattii comprises VGI, VGII, and VGIV (all serotype B), VGII, and VGIV (both serotype C) (25) . Molecular type VGII has been of particular interest in recent years due to the emergence of the novel subtypes VGIIa, VGIIb, and VGIIc; mo-lecular types VNI to VNIV and VGI to VGIV also have been designated AFLP1 to AFLP3 and AFLP4 to AFLP7, respectively (4, 6, 7) . Identification of these different molecular types has been associated with differences in antifungal susceptibility and virulence (4, 6-11, 22, 25, 33, 51) .
In addition to the different amphotericin B formulations, fluconazole and itraconazole are recommended as primary alternative induction treatments for infections caused by C. neoformans and C. gattii and voriconazole and posaconazole as salvage consolidation therapies (35, 38) ; fluconazole is also the drug of choice for lifelong suppressive (maintenance) therapy or primary therapy in some areas (24) . The azoles block the pathway of ergosterol biosynthesis by inhibiting the 14-␣-lanosterol demethylase enzyme, which is coded by the CYP51 gene in C. neoformans (CnCYP51; also called ERG11) (46) . The wide use of fluconazole and other triazoles has led to in vitro resistance among Candida and Cryptococcus isolates, especially to fluconazole more than to the newer triazoles, voriconazole, and posaconazole (38) . Two azole resistance mechanisms have been identified in C. neoformans (18, 32, 46, 54) .
The use of standard testing methods has allowed the recognition of antifungal resistance, as well as the proposal of clinical breakpoints (CBPs) for Candida spp. and epidemiological cutoff values (ECVs) for Aspergillus spp. by the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial Susceptibility Testing (AFST-EUCAST) (19-21, 40, 42, 44, 47) . More recently, CLSI amphotericin B and flucytosine ECVs were defined for the Cryptococcus neoformans-Cryptococcus gattii species complex (22) . CBPs are based on MIC distributions, pharmacokinetic and pharmacodynamic (PK/PD) parameters, animal studies, and clinical outcomes to therapy, while the ECV is based mostly on MIC distributions. Numerous surveys indicate that CLSI MICs are Յ16 g/ml (fluconazole) and Յ0.5 g/ml (the other three triazoles) for most C. neoformans and C. gattii isolates (5, 9, 10, 16, 24, 43, 50) . In the last few years, azole (mostly fluconazole) antifungal susceptibility differences have been reported for these two species and for their molecular types and serotypes (10, 11, 25, 33, 50, 51) . However, CBPs or ECVs based on data from multiple laboratories are not available for either C. neoformans or C. gattii versus the triazoles. ECVs defined in the present study could help to characterize the susceptibility of these species and to monitor the emergence of strains with mutations that could lead to reduced antifungal susceptibility to fluconazole, itraconazole, posaconazole, and voriconazole.
The purpose of the study was dual: (i) to define wild-type (WT; population of isolates in a species-drug combination with no detectable acquired resistance mechanisms) (14, 52) susceptibility endpoint distributions of each species/molecular type and triazole combination originating from at least 3 laboratories and (ii) to propose ECVs (highest WT susceptibility endpoint) of four triazoles. We aggregated the CLSI RPMI broth microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole obtained in 15 to 24 laboratories (2,985 to 5,733 MICs for C. neoformans and 705 to 975 MICs for C. gattii [species/molecular type and agent/combination dependent]) in Europe, the United States, Argentina, Australia, Canada, Cuba, Brazil, India, Mexico, and South Africa. The 220 to 359 MICs that were obtained using the alternative CLSI yeast nitrogen base (YNB) broth (12, 13) for C. neoformans were analyzed separately. Chagas-FIOCRUZ, Rio de Janeiro, Brazil. Species and molecular type identification were performed at each medical center using standard methodologies (8, 11, 25, 28, 33, 36, 51) . We have aggregated the maximum available CLSI data from each laboratory and agent as follows: 2,985 posaconazole, 4,019 itraconazole, 4,693 voriconazole, and 5,733 fluconazole MICs for C. neoformans (including MICs for the VNI to VNIV isolates) and 705 posaconazole, 828 itraconazole, 923 voriconazole, and 975 fluconazole MICs for C. gattii (including those for the VGI to VGIV isolates) (8, 11, 24, 25, 26, 33, 36, 51) . Sets of 220 (itraconazole) to 359 (fluconazole) MICs obtained using CLSI YNB broth instead of the CLSI RPMI medium (12) for C. neoformans were also available and analyzed separately. One or both quality control (QC) isolates (Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258) were used by the participant laboratories (Table 1) (12, 13) .
MATERIALS AND METHODS

Isolates
Antifungal susceptibility testing. In order to include MIC results in the total set of available aggregated CLSI data from the participant laboratories (Tables 2 to 5), triazole MICs were obtained at each center by following the CLSI M27-A3 broth microdilution method (standard RPMI 1640 broth [0.2% dextrose], final inoculum concentrations that ranged from 0.4 ϫ 10 3 to 5 ϫ 10 3 CFU/ml, and 72 h of incubation); MICs were the lowest drug concentrations that produced Ն50% growth inhibition compared to the growth control (12) . Testing conditions and interpretation of MICs were otherwise identical for those isolates grown in CLSI YNB broth. MIC data for the two QC reference strains, utilized during the years of testing in each center, were obtained each time that a set of isolates was tested following the CLSI M27-A3 broth microdilution method (12, 13) .
Definitions. The ECV, a term previously used in similar fungal reports and also known as the CO WT , is the highest wild-type (WT) cutoff susceptible value (19) (20) (21) (22) 44) . ECVs are based on MIC distributions where there are two distinct populations: (i) the WT population of isolates/MICs with no detectable acquired or mutational resistance to the drug being evaluated and (ii) the non-WT population or isolates that harbor one or more resistance markers (14, 52) . A non-WT organism shows reduced susceptibility to the agent being evaluated compared to the WT population, but it may or may not respond to treatment to the drug being evaluated. When data pertaining to the establishment of clinical breakpoints (CBPs) are not available, ECVs serve as an early indication of emerging changes in the patterns of susceptibility of organisms to the agent being evaluated.
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C. gattii
RESULTS AND DISCUSSION
The ultimate goal of susceptibility testing is to predict with some reliability the clinical outcome when an infected patient is treated with the specific agent evaluated and is referred to as the CBP (14, 30) . CBPs are based on the correlation of in vitro data, or the MIC for the infecting pathogen, with clinical and microbiological outcomes in order to differentiate an organism as treatable or nontreatable (14, 30) . On the other hand, and as previously defined, ECVs are based on MIC distributions that comprise the WT and non-WT populations; the ECV is the highest MIC that belongs to the WT population. While CBPs predict clinical outcome of therapy, the role of the ECV is to detect emerging resistance or those non-WT strains with reduced susceptibility (due to mutations) to the agent being evaluated. Attempts to correlate in vitro fluconazole results with clinical outcome have not been successful (15, 55) and, to our knowledge, have not been reported for the other three triazoles. Therefore, CBPs for either C. neoformans or C. gatti infections versus any antifungal agent are not available due to the paucity of data on PK/PD and clinical outcomes compared to MICs. However, the ECVs of the four triazoles established in the present study for C. neoformans and C. gattii may identify the non-WT clinical isolates and serve as an early indication of emerging changes in the susceptibility patterns of these organisms. Even though cryptococcal meningitis and other infections decreased with the use of antiretroviral therapies in developed countries, these infections are still a major problem among immunosuppressed patients and in certain geographical areas. The triazoles, especially fluconazole, are primary or salvage therapeutic agents for cryptococcal infections (2, 38) . Despite standardization efforts, variability is common during interlaboratory comparisons of MIC results (12, 13) . Table 1 depicts the MIC data obtained in participant laboratories for one or both QC isolates (overall range and individual modes), C. parapsilosis ATCC 22019 and C. krusei ATCC 6258, when clinical isolates were tested. As in previous CLSI ECV studies (19) (20) (21) (22) , the majority of MIC ranges were within the CLSI established limits for the two QC strains (Ն98%), with a certain degree of interlaboratory modal variability (mostly Ϯ2-fold dilution); inconsistencies were more frequent when testing itraconazole, where MICs were outside the range of 0.8 to 5% for C. parapsilosis ATCC 22019 (1 laboratory) and C. krusei ATCC 6258 (4 laboratories). Intralaboratory reproducibility was excellent in the laboratory using the CLSI YNB medium (data not shown). Similar modal variability was also observed among the laboratories for the clinical Cryptococcus spp. isolates in this and previous multicenter studies establishing ECVs of several antifungal agents for Aspergillus spp. and Cryptococcus spp. (19) (20) (21) (22) . The most probable reason is the individual interpretations of MIC endpoints, and/or it may be due to the use of different lots of antifungal powders.
The aggregated MIC distributions of the four triazoles for C. neoformans and C. gattii (for nontyped and typed isolates) are depicted in Tables 2 to 5, which also list single-laboratory distributions for C. neoformans (CLSI YNB data). Fluconazole modal MICs measured in RPMI medium were 1 to 4 g/ml for C. neoformans typed and nontyped isolates, with the lowest mode for VNIV. Modes were consistently higher among the C. gattii groups (4 to 16 g/ml), with the highest for VGIIc ( Table 2 ). Fluconazole modes from individual contributing laboratories were either 2 or RPMI  N  12  3,473  34  412  814  1,090  748  252  92  20  6  5  VNI  Y  5  1,089  35  48  100  385  376  119  19  5  1  1  VNII  Y  3  27  5  6  9  3  4  VNIII  Y  3  51  9  7  19  12  3  1  VNIV  Y  3  53  13  19  12 4 g/ml for C. neoformans nontyped and most typed isolates; the exception was the mode (1 g/ml) from two of the four laboratories that contributed data for VNIV, but the number of isolates was small. Overall, our values reflect previous fluconazole MIC 90 s and modes for similar sets of typed or nontyped C. neoformans and C. gattii isolates and the fact that MICs are usually higher (MIC 90 s and modes, 2 to 8 g/ml versus 8 to 32 g/ml) for C. gattii independent of testing conditions (10, 16, 23, 50) . However, the MIC 90 has also been higher (16 g/ml) for C. neoformans nontyped isolates (5, 39) , but some of those results were obtained by the EUCAST method (39) . The modal MIC for C. neoformans measured in CLSI YNB medium was higher (mode, 8 g/ml) than those measured in CLSI RPMI medium; this discrepancy has been reported previously (10, 55) . These results further underline the variability of susceptibility test results using different methodologies. Modes for the other three triazoles were more species-, molecular type-and medium-dependent (Tables 3 to 5 ). In agreement with previous data (10, 16, 23, 50) , the MICs of itraconazole, posaconazole, and voriconazole for C. gattii also tended to be higher (modes, 0.06 to 0.5 g/ml, typed and nontyped isolates) than those for C. neoformans (modes, 0.016 to 0.12 g/ml, typed and nontyped isolates), with the highest modes for VGIIb and VGIIc (voriconazole mode, 0.25 g/ml) and VGIIc and VGIV (itraconazole and posaconazole mode, 0.5 g/ml) ( Tables 3 to 5 ). Reflecting fluconazole distributions, modes from individual participant laboratories were within one dilution of each other (modes, 0.12 to 0.25 g/ml and 0.06 to 0.12 g/ml for itraconazole and both posaconazole and voriconazole, respectively). Based on these data and the wide geographical range over which the MICs have been collected in the present study, we surmise that we are presenting valid data. Table 6 depicts the proposed fluconazole, itraconazole, posaconazole, and voriconazole ECVs for the aggregated distributions of C. neoformans and C. gattii (typed or nontyped isolates). ECVs were proposed when the data originated from at least three laboratories using the statistical methodology that comprised Ն95% of the modeled population instead of the observed population; the values that comprised Ն97.5 and Ն99% of the population were also obtained. Some of the proposed ECVs were based on small numbers of isolates (Tables 2 to 5 , n Ͻ100), and those could be considered tentative values. Although three other distributions (fluconazole versus VNIV and itraconazole versus VNIII and VNIV) originated in at least three laboratories, statistical fitting was not possible and ECVs were not proposed. The CLSI fluconazole ECVs for the different subsets of C. neoformans isolates were either 8 g/ml (VNI) or 16 g/ml (nontyped and VNIII isolates). Fluconazole ECVs for C. gattii ranged from 8 g/ml (nontyped, VGI, VGIIa, and VGIII isolates) to 32 g/ml (VGII). It is interesting that a fluconazole MIC of Ն16 g/ml is anecdotally believed to be the resistance cutoff, but this value can be perceived here as a non-WT value for some of the subsets of the two species. So far mutations have not been observed when the fluconazole MIC is Յ16 g/ml (49) . ECVs of the three other triazoles were also species-, agent-, and molecular type-dependent as follows: (i) itraconazole ECVs of 0.25 g/ml (VNI), 0.5 g/ml (nontyped isolates of both species and VGI to VGIII), and 1 g/ml (VGIV); (ii) posaconazole ECVs of 0.25 g/ml (C. neoformans nontyped and VNI) and 0.5 g/ml (C. gattii nontyped and VGI); and (iii) voriconazole ECVs of 0.12 g/ml (VNIV), 0.25 g/ml (nontyped isolates of both species, VNI, VNIII, VGII, and VGIIa), and 0.5 g/ml (VGI). The overall trend was that ECVs for C. neoformans molecular types were lower than those for C. gattii. Previous MIC 90 s and modes of these three triazoles have been similar (9, 10, 23, 44, 50) . Because the distributions in CLSI YNB originated from a single laboratory, ECVs were not proposed for these distributions (Tables 2, 3, and 5). Tentative values of 16 g/ml for fluconazole (encompassing 97.8% of the isolates), 2 g/ml for itraconazole (encompassing 99.5% of the isolates), and 0.5 g/ml for voriconazole (encompassing 100% of the isolates) can be suggested for CLSI YNB MICs (data not shown). Additional data from other laboratories using either CLSI YNB or CLSI RPMI medium (at least three laboratory subsets), or for subsets comprising at least 100 isolates, should corroborate/extend our tentative values. ECVs encompassing both Ն97.5% and Ն99% of the modeled population were mostly the same or one dilution higher (Table 6) ; the same applied when all isolates of each species were pooled together, e.g., all VGIIs (data not shown). Although the proposed ECVs in the present study are not predictors of clinical outcome, these critical drug concentrations may aid in identifying those cryptococcal strains with decreased susceptibility to the triazole being evaluated. The frequency of MICs above the ECV (non-WT) varied according to the distribution analyzed ( Table 6 ). The rate of fluconazole non-WT MICs was higher (1.7 to 9.5%) than those of the other three triazoles (0 to 5.7%). Between the two species, the fluconazole and itraconazole rates of non-WT MICs were usually lower for all C. neoformans isolates (1.1 to 2.9%) than for all C. gatti isolates (0 to 9.5%) and almost the same for voriconazole. In contrast, the rate was lower for posaconazole (0.3 to 5.7% versus 0.5 to 1.5%). However, C. gattii MIC distributions were small (Tables 2 to 5). Although cryptococcal infections caused by both species are clinically similar, there is more of a delayed treatment response and other complications in infections caused by C. gattii than those due to C. neoformans (38) . In vitro resistance to fluconazole (3.1% to 46%) and itraconazole (0.5% to 17.4%) has been reported for C. neoformans isolates; although the itraconazole cutoff was Ն1 g/ml, it was variable for fluconazole (Ն16 g/ml and Ն64 g/ml) (5, 16, 39) . Based on arbitrary voriconazole cutoffs of Ն2 g/ml for both Cryptococcus spp., in vitro resistance to this agent has been low or absent (0% to 0.9%) (23, 24, 43, 50) ; the same applies to posaconazole (23, 24, 43) . Species identification and antifungal susceptibility testing emphasize the utility of WT cutoffs as a practical tool to detect triazole resistance among Cryptococcus isolates. Our results also point out that ECVs should be species-specific and, for this fungal group, molecular type-specific. This information is important; it has been reported that 20% of cryptococcal infections are caused by multiple strains or molecular types, but generally only one isolate per infection is tested (17) .
During the 1990s, the early years of fluconazole therapy, relapses were not associated with in vitro resistance due to the higher initial fluconazole doses (38) . Since then, relapses have been attributed to the excessive use of this agent as primary and prophylactic therapies, as well as the use of suboptimal doses for long periods of time, especially among AIDS patients. As relapses began to be associated with high fluconazole MICs and/or a 4-fold MIC increase (1, 24, 37, 38) , several aspects of sterol metabolism in these isolates were investigated to determine azole resistance mechanisms in C. neoformans. A point mutation in the ERG11 (CnCYP51) gene resulting in a G484S substitution in the target enzyme has been observed in C. neoformans strains with high fluconazole MICs (Ն32 g/ml); this mutation alters the affinity of the drug for the target enzyme (32, 48, 54) . The overexpression of the gene CnAFR1 that encodes the membrane efflux pumps has been found to reduce cell drug (fluconazole) content in C. neoformans (29, 45) . Azole cross-resistance among cryptococcal strains is rare; the lack of cross-resistance between itraconazole and fluconazole has been attributed to the dual itraconazole target in C. neoformans, which appears to block both the lanosterol 14-␣-demethylase and the NADH-dependent 3-ketosteroid reductase (37) . This was recently confirmed in a C. neoformans isolate, where cross-resistance was evident between fluconazole (MICs Ͼ 64 g/ ml) and voriconazole (MICs Ն 2 g/ml) but not with itraconazole. In contrast, increased itraconazole susceptibility (lower MIC) and no change in the posaconazole MIC were observed (49) . A missense mutation (Y145F substitution) in the ERG11 gene (P450Dm, ERG11) led to fluconazole-voriconazole cross-resistance. In addition, a high level of heteroresistance to fluconazole, more commonly observed in C. gattii than in C. neoformans isolates, was observed in the same isolate (49, 53) . Some of these findings explain the different rates of non-WT isolates found in the present study.
Based on small numbers of patients/isolates and the use of different methodologies, correlations between a variety of fluconazole MICs and clinical outcomes (1, 3, 34) have been reported: more rapid CSF sterilization and infection eradication has been associated with MICs of 4 to 8 g/ml and clinical failure or recurrence with MICs of Ն16 g/ml. In addition, either a lack of correlation (15) or a relationship that was dependent on the combination of high MICs with other factors have been documented (55) . A more useful MIC cutoff that would predict azole failure in treatment of cryptococcal infections has also been hampered by other factors that influence outcome to therapy in addition to microbiological clearance (17, 37) . Conversely, our ECVs could aid in the separation of WT strains from those with reduced azole susceptibility or non-WT isolates. However, more information is needed regarding azole resistance in C. neoformans and C. gattii, especially for posaconazole and voriconazole, as well as the relationship between non-WT strains and resistance mechanisms.
In conclusion, the ECVs of fluconazole (8 to 32 g/ml), itraconazole (0.25 to 1 g/ml), posaconazole (0.25 to 0.5 g/ml), and voriconazole (0.12 to 0.25 g/ml) proposed in this study for the C. neoformans-C. gattii species complex are species-and molecular type-specific, but these differences were mostly within one dilu-tion. Further investigation should determine the relationship between molecular mechanisms of triazole resistance and our proposed non-WT values. Some of the distributions were small (especially for various C. neoformans molecular types), and continuing surveillance should either corroborate or expand the information provided in the present study. In the absence of CBPs, these ECVs may be clinically useful in detecting non-WT isolates that have reduced susceptibility to itraconazole, posaconazole, and voriconazole or that harbor fluconazole resistance mechanisms. ECVs should be included in the revised version of the CLSI M27-A3 document.
